The Form 144 filing by CEO Grant Pickering is a routine advance notice of intent to sell a modest number of shares relative to the company's $8.1B market cap. The proposed sale (~$1.30M) is consistent with normal portfolio diversification and does not signal distress. Monitor for actual Form 4 filings to confirm execution, but no immediate trading action is warranted.
PCVX drugs
PCVX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 29 $57.72entry
- T+1 · 5mo ago +0.71%α −0.07% · $58.13
- T+5 · 4mo ago −1.32%α −2.70% · $56.96
- T+20 · 4mo ago −5.30%α −5.02% · $54.66
- T+60 · 8w ago +2.25%α −2.13% · $59.02
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CEO Grant Pickering filed a Form 144 notice of intent to sell 24,237 shares of Vaxcyte (PCVX) with an approximate market value of $1.30M, alongside 2,000 additional shares from family trusts. The filing signals insider selling intent but is a routine diversification move by the CEO, not a distress signal, given the company's $8.1B market cap and strong institutional backing.
Key Facts
- CEO Grant Pickering filed Form 144 to sell 24,237 shares of Vaxcyte common stock, valued at approximately $1.30M based on the filing date.
- An additional 2,000 shares are being sold via family trusts (Claire Pickering 2020 Delaware Trust and Benjamin Pickering 2020 Delaware Trust), each valued at ~$52,500.
- The shares to be sold were acquired through RSU vesting (2023-2025), founder shares (2013), and prior RSU vesting (2024).
- The filing is an advance notice of intent to sell, not a completed transaction, the sale may not occur.
- Recent insider activity (30d) shows 9 sells totaling $1.3M, consistent with routine insider selling patterns.
Financial Impact
CEO proposes to sell ~24,237 shares worth ~$1.30M, representing a small fraction of the $8.1B market cap and likely a small portion of the insider's total holdings.
Risk Factors
- Insider selling could be misinterpreted by the market as a lack of confidence, though the amount is small relative to market cap.
- The sale is not yet executed, the insider may choose not to sell, making the filing a non-event.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001969223-26-000725 |
| Document: 0001969223-26-000725-index.html | 0001969223-26-000725 |
| Document: 0001969223-26-000725.txt | 0001969223-26-000725 |
Track record
29 reports on PCVX
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +10.87% at T+5 after the Oct 8, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $62.40 Now $63.37 +1.55% settles Dec 15
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $64.69 Now $63.37 −2.04% settles Dec 11
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $63.89 Now $63.37 −0.81% settles Dec 7
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $63.89 Now $63.37 −0.81% settles Dec 7
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $61.92 Now $63.37 +2.34% settles Dec 4
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $61.92 Now $63.37 +2.34% settles Dec 4
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $60.81 Now $63.37 +4.21% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $60.81 Now $63.37 +4.21% settles Dec 2
- Oct 9, 20265w ago 8-K Bearish 6/10 Entry $70.65 to $67.53 Now $63.37 +10.30% ▲ +4.42% +1.15% vs SPY
- Oct 8, 20265w ago 424B5 Bearish 6/10 Entry $71.38 to $63.89 Now $63.37 +11.22% ▲ +10.49% +4.93% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers